Stephen Krieger, MD

Stephen Krieger, MD, speaks to the known effects of disease-modifying therapies for multiple sclerosis on cognitive function, among other interventions.

Stephen Krieger, MD, discusses how cognition is defined in multiple sclerosis and the tools to evaluate patients' cognitive performance.

Stephen Krieger, MD; Daniel Bandari, MD, MS; Bruce Hughes, MD; Mitzi Williams, MD; and Heidi Crayton, MD, provide key takeaways for the treatment of patients with multiple sclerosis.

A panel of experts discuss COVID-19 vaccine efficacy for patients undergoing treatment for multiple sclerosis.

An expert panel considers patients with multiple sclerosis who may need to discontinue treatment during pregnancy.

Stephen Krieger, MD; Daniel Bandari, MD, MS; Bruce Hughes, MD; Mitzi Williams, MD; and Heidi Crayton, MD, review data on short-term interruption of ponesimod vs teriflunomide when treating multiple sclerosis.

Stephen Krieger, MD; Daniel Bandari, MD, MS; Bruce Hughes, MD; Mitzi Williams, MD; and Heidi Crayton, MD, discuss their approach to switching treatments for patients with multiple sclerosis and the timing between therapies.

Stephen Krieger, MD; Daniel Bandari, MD, MS; Bruce Hughes, MD; Mitzi Williams, MD; and Heidi Crayton, MD, share their thoughts on sequencing disease-modifying therapies when treating patients with multiple sclerosis.

Stephen Krieger, MD; Daniel Bandari, MD, MS; Bruce Hughes, MD; Mitzi Williams, MD; and Heidi Crayton, MD, examine the safety of sphingosine 1-phosphate receptor modulators for the treatment of multiple sclerosis.

An expert panel talks about the preservation of brain health regarding the use of sphingosine 1-phosphate receptor modulators to treat multiple sclerosis.

Stephen Krieger, MD; Daniel Bandari, MD, MS; Bruce Hughes, MD; Mitzi Williams, MD; and Heidi Crayton, MD, review data on ponesimod vs teriflunomide for the treatment of female patients with multiple sclerosis who are of childbearing age.

An expert panel provides an overview of sphingosine-1-phosphate receptor modulators and their use in the treatment of multiple sclerosis.

Stephen Krieger, MD; Daniel Bandari, MD, MS; Bruce Hughes, MD; Mitzi Williams, MD; and Heidi Crayton, MD, review the OPTIMISE study and reflect on the differences between patient characteristics in clinical trial settings vs clinical practice.

Stephen Krieger, MD; Daniel Bandari, MD, MS; Bruce Hughes, MD; Mitzi Williams, MD; and Heidi Crayton, MD, discuss the prevalence of comorbidities in patients with multiple sclerosis.

The neurologist at the Corinne Goldsmith Dickinson Center for MS offered a brief overview of his experience at the 2022 IFN conference held in New York City on September 23-24. [WATCH TIME: 4 minutes]

Experts in neurology share practice pearls to optimize the treatment for patients with multiple sclerosis.

Heidi Crayton, MD; Jacqueline Nicholas, MD; and Flavia Nelson, MD, share their excitement for the future of multiple sclerosis treatment and comment on emerging therapies.

Experts in neurology provide insight into treatment selection and sequencing in patients with multiple sclerosis, focusing on S1P modulators.

The neurologist at the Corinne Goldsmith Dickinson Center for MS offered an overview of the State of the Science Summit that was held on June 30, 2022, with a variety of expert clinicians from Mount Sinai. [WATCH TIME: 7 minutes]

Dr Jacqueline Nicholas hypothesizes about the utility of neurofilaments as a biomarker of disease severity in patients with multiple sclerosis.

Heidi Crayton, MD, and Jacqueline Nicholas, MD, review the importance of long-term safety data in the management of patients with multiple sclerosis, and Flavia Nelson, MD, discusses her approach to counseling patients on the safety considerations regarding new S1P modulating agents.

Dr Flavia Nelson comments on the impact of S1P modulators on brain volume measures; highlighting thalamic atrophy and its correlation with brain volume loss in MS.

Experts in neurology review data surrounding the role of disease-modifying therapies in preventing grey matter brain atrophy and cognitive decline.

Dr Heidi Crayton discusses the role of S1P receptor modulators in the management of patient with multiple sclerosis.

Flavia Nelson, MD, provides an overview of available brain atrophy data and cognition research in patients with multiple sclerosis.

Jacqueline Nicholas, MD, provides insight into challenges inherent to the assessment of brain health in patients with multiple sclerosis [MS].

Heidi Crayton, MD, shares a patient story to highlight the importance of imaging modalities in identifying brain loss and atrophy in patients with multiple sclerosis [MS].

Experts in neurology comment on the level of patient awareness surrounding cognitive decline in multiple sclerosis and highlight how to engage patients in difficult conversations regarding their cognitive health.

Heidi Crayton, MD; Jacqueline Nicholas, MD; and Flavia Nelson, MD, share their practices and diagnostic assessments for cognitive decline in their patients with multiple sclerosis.

Experts in neurology discuss the multiple ways in which cognitive decline can present in their patients with multiple sclerosis and highlight how they assess for it.